JnJ eyes expanded USFDA approval for Caplyta for prevention of relapse in schizophrenia Ruchika Sharma9 July 2025 12:30 PM ISTTitusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based...
JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations Ruchika Sharma6 July 2025 12:30 PM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced the submission of an extension of indication application...
Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International Ruchika Sharma22 Jun 2025 5:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
JnJ seeks USFDA nod of Stelara for pediatric Crohn's disease Ruchika Sharma18 Jun 2025 11:58 AM ISTHorsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA (ustekinumab) for the...
JnJ elects JPMorganChase President Daniel Pinto to its Board of Directors Ruchika Sharma11 Jun 2025 4:07 PM ISTNew Brunswick: Johnson & Johnson has elected JPMorganChase's President Daniel Pinto to its Board of Directors.Pinto is a prominent business...
Icotrokinra results show significant skin clearance in patients with difficult to treat scalp, genital psoriasis: JnJ Ruchika Sharma12 May 2025 10:30 AM ISTSpring House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the...
Johnson & Johnson Medtech, Qure.ai partner to enhance early detection of lung cancer in India Ruchika Sharma11 May 2025 11:00 AM ISTMumbai: Johnson & Johnson MedTech has onboarded Qure.ai as a strategic partner with Johnson & Johnson Private Limited, a Johnson &...
JnJ backed HistoSonics explores sale at USD 2.5 billion valuation: Report Ruchika Sharma2 May 2025 10:30 AM ISTJohnson & Johnson backed HistoSonics is exploring a potential sale at a valuation of over USD 2.5 billion, following a wave of...
JnJ Imaavy gets USFDA okay for generalized myasthenia gravis Ruchika Sharma1 May 2025 1:15 PM ISTSpring House: Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for IMAAVY (nipocalimab-aahu), a human...
Johnson & Johnson gets CDSCO Panel for additional indication of Amivantamab Liquid Concentrate for Infusion Dr. Divya Colin12 April 2025 5:45 AM ISTNew Delhi: In a significant development, the drug major Johnson and Johnson has got the go-ahead from the Subject Expert Committee (SEC) functional...
JnJ closes Intra-Cellular Therapies acquisition Ruchika Sharma3 April 2025 10:30 AM ISTNew Brunswick: Johnson & Johnson has announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is...
USFDA nod to JnJ Tremfya for Crohn's disease Ruchika Sharma21 March 2025 10:30 AM ISTHorsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration (FDA) for TREMFYA...
